Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3
Karyopharm Tapped Lori Macomber Of Legend Biotech As CFO, Effective January 3
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company.
Karyopharm Therapeutics Inc. (納斯達克:KPTI)，一家領先新型癌症治療的商業階段藥品公司，今天宣佈任命Lori Macomber爲執行副總裁、財務長和財務主管，任職於2025年1月3日。在這個職位上，Macomber女士將負責領導和指導公司的財務活動。
Ms. Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals. Most recently, she served as Chief Financial Officer at Legend Biotech Corporation, a publicly traded, commercial-stage biopharmaceutical company. Previously, Ms. Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.
Macomber女士擁有超過20年的多元化經驗，領導增長並推動生命科學公司的財務戰略。她在從初創公司到財富500強公司的財務管理方面有着良好的業績記錄，同時還成功支持了多種合作伙伴關係、業務發展活動和許可交易。最近，她擔任傳奇生物公司（Legend Biotech Corporation）的財務長，該公司是一家上市的商業階段生物製藥公司。在此之前，Macomber女士在阿美特克（Ametek PDS）、Cello Health、輝瑞（Pfizer，前身爲Pharmacia）等公司擔任了越來越多的領導職務。Macomber女士獲得了賓夕法尼亞州立大學的會計學理學士學位，並且是一名註冊公共會計師。